Skip to main content
Advertisement
Advertisement

AGIO

AGIO logo

Agios Pharmaceuticals, Inc.

34.63
USD
Sponsored
+1.08
+3.22%
Sep 09, 15:59 UTC -4
Closed
exchange

After-Market

35.70

+1.07
+3.09%

AGIO Earnings Reports

Positive Surprise Ratio

AGIO beat 29 of 42 last estimates.

69%

Next Report

Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$54.83M
/
-$1.23
Implied change from Q2 26 (Revenue/ EPS)
+22.55%
/
-27.22%
Implied change from Q3 25 (Revenue/ EPS)
+325.73%
/
-30.90%

Agios Pharmaceuticals, Inc. earnings per share and revenue

On Jul 30, 2026, AGIO reported earnings of -1.69 USD per share (EPS) for Q2 26, beating the estimate of -1.70 USD, resulting in a 0.66% surprise. Revenue reached 44.74 million, compared to an expected 26.03 million, with a 71.89% difference. The market reacted with a -6.46% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -1.23 USD, with revenue projected to reach 54.83 million USD, implying an decrease of -27.22% EPS, and increase of 22.55% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-
Surprise
-
FAQ
For Q2 2026, Agios Pharmaceuticals, Inc. reported EPS of -$1.69, beating estimates by 0.66%, and revenue of $44.74M, 71.89% above expectations.
The stock price moved down -6.46%, changed from $35.01 before the earnings release to $32.75 the day after.
The next earning report is scheduled for Oct 28, 2026.
Based on 7 analysts, Agios Pharmaceuticals, Inc. is expected to report EPS of -$1.23 and revenue of $54.83M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement